Emcure Pharmaceuticals Ltd Stock Price Today (NSE: EMCURE)
Fundamental Score
Emcure Pharmaceuticals Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Emcure Pharmaceuticals Ltd share price today is ₹1595.50, up +4.14% on NSE/BSE as of 30 March 2026. Emcure Pharmaceuticals Ltd (EMCURE) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹27.17K (Cr). The 52-week high for EMCURE share price is ₹1671.80 and the 52-week low is ₹889.00. At a P/E ratio of 33.89x, EMCURE is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 18.51% and a debt-to-equity ratio of 0.35.
Emcure Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Emcure Pharmaceuticals Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Emcure Pharmaceuticals Share Price: A Financial Analysis
The pharmaceutical industry is currently navigating a complex landscape of increasing regulatory scrutiny and growing demand for generic drugs. Against this backdrop, this analysis examines the financial standing of Emcure Pharmaceuticals Ltd, focusing on its valuation and profitability metrics. Specifically, we'll look at the "Emcure Pharmaceuticals share price", which currently stands at ₹1515.70, and how it relates to the company's performance relative to its peers.
Emcure Pharmaceuticals’ Price-to-Earnings (PE) ratio is presently 33.89. This indicates what investors are willing to pay for each rupee of Emcure's earnings. When considering management quality, it's useful to contrast Emcure with
Mankind Pharma Ltd. While both companies operate within the pharmaceutical sector, differences in management strategies and operational efficiencies can significantly impact their respective valuations and future growth prospects. A deeper dive into their leadership track records and strategic decisions is crucial for a comprehensive understanding.A critical factor contributing to Emcure's potential economic moat is its Return on Capital Employed (ROCE) of 20.72%. ROCE demonstrates how effectively a company is using its capital to generate profits. A consistently high ROCE, like Emcure's, suggests that the company possesses a competitive advantage, be it through cost efficiencies, differentiated products, or strong brand recognition. This higher return implies that Emcure is better at generating profit relative to its capital than some of its peers. This suggests Emcure is relatively efficient.
This financial analysis is based on publicly available data and is part of a broader 80-parameter fundamental audit, verified by Sweta Mishra, to ensure a thorough assessment of Emcure Pharmaceuticals' financial health. This report provides an observational perspective on Emcure Pharmaceuticals' current financial standing based on the data available and comparative analysis with peers like Smruthi Organics Ltd and Balaxi Pharmaceuticals Ltd. It does not constitute any investment recommendation.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Emcure Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of EMCURE across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Strong Return on Equity (18.51%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (20.72%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (20.45%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (25.13%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Excellent EPS Growth (34.92% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (36.18% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Strong Interest Coverage (9.74x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹2541.67 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Risk Factors
1 factors identified
Limited Institutional Interest (FII+DII: 7.65%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Emcure Pharmaceuticals Ltd Financial Statements
Comprehensive financial data for Emcure Pharmaceuticals Ltd including income statement, balance sheet and cash flow
About EMCURE (Emcure Pharmaceuticals Ltd)
Emcure Pharmaceuticals Ltd is a global pharmaceutical company committed to developing, manufacturing, and marketing a diverse portfolio of pharmaceutical products to improve patien...t outcomes worldwide. With a strong emphasis on innovation and quality, Emcure focuses on addressing unmet medical needs across a broad range of therapeutic areas, including women's health, oncology, and cardiovascular disease. The company leverages advanced technologies and a dedicated team of researchers to create effective and affordable treatment options for patients around the globe. Emcure’s dedication to ethical business practices and its commitment to corporate social responsibility have established it as a respected and reliable partner within the healthcare industry. Emcure operates across various specialized divisions, each focusing on specific therapeutic areas and patient populations. The company's extensive product line encompasses a wide range of dosage forms, including tablets, capsules, injectables, and topical formulations. Emcure emphasizes research and development to expand its product portfolio and cater to emerging market trends. The company's manufacturing facilities are equipped with state-of-the-art equipment and adhere to stringent quality control standards, ensuring that all products meet the highest levels of safety and efficacy. With a comprehensive distribution network, Emcure strives to make its medicines accessible to patients in diverse geographic locations. Emcure has established strategic alliances and collaborations to expand its global reach and enhance its product offerings. These partnerships allow Emcure to leverage external expertise and resources to accelerate the development and commercialization of novel therapies. The company also actively engages in educational initiatives to raise awareness of important health issues and promote the appropriate use of medications. Emcure's commitment to innovation, quality, and patient well-being drives its continued growth and reinforces its position as a leading pharmaceutical company dedicated to improving global health.
Company Details
Key Leadership
Corporate Events
Latest News
EMCURE Share Price: Frequently Asked Questions
What is the current share price of Emcure Pharmaceuticals Ltd (EMCURE)?
As of 30 Mar 2026, 12:06 pm IST, Emcure Pharmaceuticals Ltd share price is ₹1595.50. The EMCURE stock has a market capitalisation of ₹27.17K (Cr) on NSE/BSE.
Is EMCURE share price Overvalued or Undervalued?
EMCURE share price is currently trading at a P/E ratio of 33.89x, compared to the industry average of 31.77x. Based on this relative valuation, the Emcure Pharmaceuticals Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of EMCURE share price?
The 52-week high of EMCURE share price is ₹1671.80 and the 52-week low is ₹889.00. These values are updated daily from NSE/BSE price data.
What factors affect the Emcure Pharmaceuticals Ltd share price?
Key factors influencing EMCURE share price include quarterly earnings growth (Sales Growth: 13.38%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Emcure Pharmaceuticals Ltd a good stock for long-term investment?
Emcure Pharmaceuticals Ltd shows a 5-year Profit Growth of 36.18% and an ROE of 18.51%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.35 before investing in EMCURE shares.
How does Emcure Pharmaceuticals Ltd compare with its industry peers?
Emcure Pharmaceuticals Ltd competes with major peers in the Pharmaceuticals. Investors should compare EMCURE share price P/E of 33.89x and ROE of 18.51% against the industry averages to determine competitive standing.
What is the P/E ratio of EMCURE and what does it mean?
EMCURE share price has a P/E ratio of 33.89x compared to the industry average of 31.77x. Investors pay ₹34 for every ₹1 of annual earnings.
How is EMCURE performing according to Bull Run's analysis?
EMCURE has a Bull Run fundamental score of 68.4/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does EMCURE belong to?
EMCURE operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Emcure Pharmaceuticals Ltd share price.
What is Return on Equity (ROE) and why is it important for EMCURE?
EMCURE has an ROE of 18.51%, which indicates excellent management efficiency. ROE measures how efficiently Emcure Pharmaceuticals Ltd generates profits from shareholders capital.
How is EMCURE debt-to-equity ratio and what does it indicate?
EMCURE has a debt-to-equity ratio of 0.35, which indicates moderate leverage that should be monitored.
What is EMCURE dividend yield and is it a good dividend stock?
EMCURE offers a dividend yield of 0.21%, meaning you receive ₹0.21 annual dividend for every ₹100 invested in Emcure Pharmaceuticals Ltd shares.
How has EMCURE share price grown over the past 5 years?
EMCURE has achieved 5-year growth rates of: Sales Growth 9.36%, Profit Growth 36.18%, and EPS Growth 34.92%.
What is the promoter holding in EMCURE and why does it matter?
Promoters hold 77.88% of EMCURE shares, with 0.04% pledged. High promoter holding often indicates strong management confidence in Emcure Pharmaceuticals Ltd.
What is EMCURE market capitalisation category?
EMCURE has a market capitalisation of ₹27173 crores, placing it in the Large-cap category.
How volatile is EMCURE stock?
EMCURE has a beta of N/A. A beta > 1 suggests the Emcure Pharmaceuticals Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is EMCURE operating profit margin trend?
EMCURE has a 5-year average Operating Profit Margin (OPM) of 20.45%, indicating the company's operational efficiency.
How is EMCURE quarterly performance?
Recent quarterly performance shows Emcure Pharmaceuticals Ltd YoY Sales Growth of 13.38% and YoY Profit Growth of 25.13%.
What is the institutional holding pattern in EMCURE?
EMCURE has FII holding of 3.29% and DII holding of 4.36%. Significant institutional holding often suggests professional confidence in the Emcure Pharmaceuticals Ltd stock.